Skip to main content
Premium Trial:

Request an Annual Quote

Jefferies Lowers Estimates on Nanosphere

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Jefferies on Tuesday lowered its revenue and price targets for Nanosphere, following the US Food and Drug Administration's denial of a marketing application for its Plavix (clopidogrel) metabolism test.

In a research note, analyst Jon Wood lowered 2011 revenue estimates to $3.3 million from $4.5 million, and 2012 revenue forecasts to $9 million from $17 million. He also lowered the price target on Nanosphere shares to $2 from $3.50.

Jefferies has a "Hold" rating on the company.

"While the near-term financial impact appears manageable, the event may spark concerns over the value of [Nanosphere's] sizeable (though distant) pipeline, where the bolus of its enterprise value seems concentrated," Wood said. He added that the FDA's denial could stunt Nanosphere's ability to place new Verigene instruments with customers "and impair its installed base growth trajectory, given what we perceive as few significant pipeline milestones until 2012."

Nanosphere said that it believes it can resolve the issues cited by the FDA in its denial letter and ultimately the test will gain pre-market approval. In his note, Wood agreed and said that the company plans to conduct additional clinical studies to address the deficiencies. However, he noted that the agency may take up to six months to review the revised PMA submission, which could delay commercialization of the test to the middle of 2012, assuming that Nanosphere can resubmit is application by late 2011.

In early Wednesday trading on Nasdaq, shares of Nanosphere were down 5 percent to $1.56.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.